Larazotide Acetate

Larazotide acetate is an 8-amino-acid synthetic single-chain peptide that acts as a tight junction regulator and zonulin antagonist. It is derived structurally from sequences related to zonulin (a human tight junction modulator) and the Vibrio cholerae zonula occludens toxin (ZOT). The molecule is orally administered three times daily before meals. The clinical hypothesis was that pretreatment before gluten-containing meals would prevent zonulin-induced tight junction opening, reducing the paracellular passage of gliadin peptides into the lamina propria and the later inflammatory response in celiac disease. Larazotide acetate has no FDA approval. The Phase 3 CedLara trial was discontinued in September 2023.

The molecule was originally developed by Alba Therapeutics. In February 2016, Innovate Biopharmaceuticals licensed the larazotide acetate assets. In 2019 to 2020, Innovate merged with RDD Pharma to form 9 Meters Biopharma, which continued the Phase 3 development. The 2023 discontinuation effectively ended the celiac disease clinical-development program after more than 15 years of preclinical and clinical work.

Celiac disease is an autoimmune disorder affecting approximately 1 in 100 people globally. The condition is triggered by ingestion of gluten (the protein in wheat, barley, and rye) in genetically susceptible individuals. Gluten ingestion produces inflammation of the small intestinal mucosa with villous atrophy and crypt hyperplasia. The standard treatment is strict lifetime gluten-free diet, which is the only effective intervention and the only approved approach as of May 2026. Many patients on gluten-free diet continue to experience symptoms due to inadvertent gluten exposure. The market need for an adjunct pharmacotherapy is substantial, but no drug has achieved approval.

The Clinical Evidence Base

The larazotide acetate clinical evidence is among the most extensive for any celiac disease investigational therapy.

Phase 2b trial (Leffler et al., Gastroenterology 2015). Randomized, double-blind, placebo-controlled, 12-week trial in 342 celiac disease patients on gluten-free diet. Larazotide acetate at three dose levels (0.5 mg, 1 mg, 2 mg) versus placebo, three times daily. The 0.5 mg dose met the primary endpoint of symptom improvement with statistical significance. Larazotide acetate was the first celiac disease drug to meet its primary endpoint in a Phase 2b trial.

Phase 2 gluten challenge trial. Earlier Phase 2 studies in volunteer gluten challenge contexts documented reduction in gluten-induced intestinal permeability and symptoms.

FDA Fast Track designation. Granted based on the Phase 2 evidence and the unmet medical need.

Phase 3 CedLara trial (NCT03569007). Initiated August 13, 2019, by Innovate Biopharmaceuticals. Approximately 600 patients planned. 24-week study design with 5-week screening, 12-week double-blind treatment, and 12-week safety follow-up. Adjunct therapy to gluten-free diet in patients with persistent symptoms.

September 2023 discontinuation. 9 Meters Biopharma discontinued the Phase 3 trial. The reasons were not fully disclosed publicly but related to interim analysis findings and commercial considerations.

Systematic review and meta-analysis. A 2021 systematic review of larazotide acetate randomized controlled trials documented safety and modest efficacy benefits, with the assessment that larazotide acetate may complement rather than replace gluten-free diet.

The 15-year development program produced extensive evidence of mechanism, safety, and modest clinical benefit, but in the end did not achieve the Phase 3 efficacy demonstration needed for FDA approval.

Larazotide acetate has a specific tight junction regulation mechanism that is conceptually different from immunosuppression or anti-inflammatory mechanisms.

Zonulin antagonism. Zonulin is a human protein that physiologically regulates intestinal tight junction permeability. Zonulin levels are increased in celiac disease and contribute to the increased intestinal permeability that allows gluten peptides to cross the epithelial barrier. Larazotide acetate antagonizes zonulin signaling, reducing tight junction opening in response to gluten or other triggers.

Tight junction protein redistribution. Larazotide acetate has been associated with redistribution and rearrangement of tight junction proteins (ZO-1, claudins, occludin) and actin filaments. The result is restored intestinal barrier function and reduced paracellular permeability.

Myosin light chain kinase inhibition. More recent mechanism work has linked larazotide acetate to inhibition of myosin light chain kinase (MLCK), which reduces tension on actin filaments and supports tight junction closure. This adds a complementary mechanism to the zonulin antagonism.

Reduced gliadin paracellular transport. The downstream effect is reduced passage of gliadin peptides through the paracellular pathway between intestinal epithelial cells. With reduced gliadin delivery to the lamina propria, the immune activation and inflammatory cascade is reduced.

Local intestinal action. Larazotide acetate acts locally in the intestine and has minimal systemic absorption. The local-action profile is part of the favorable safety positioning.

Pretreatment before meals. The pharmacodynamics require pre-meal dosing. Larazotide acetate must be present in the intestine before gluten arrives to prevent zonulin-induced tight junction opening. The thrice-daily before-meals dosing schedule reflects this pharmacodynamic requirement.

The mechanism is distinct from approaches that target gluten degradation (enzymes like AN-PEP, latiglutenase) or immune modulation (vaccines, immunosuppressants). Larazotide acetate addresses the intestinal barrier dysfunction rather than the gluten antigen or the immune response.

Regulatory status

No FDA approval, no EMA approval, no marketing authorization in any country.

Phase 3 program discontinued September 2023. 9 Meters Biopharma effectively ended active commercial development of larazotide acetate for celiac disease.

Other indications. The tight junction regulator mechanism has continued research interest in other conditions with intestinal barrier dysfunction including IBS, Crohn's disease, environmental enteropathy, and others. No active commercial development programs in these indications have been announced as of May 2026.

FDA Fast Track designation. Was granted but no submission has been made.

Compounding status. Larazotide acetate is not on the FDA Category 2 bulks list.

WADA status. Larazotide acetate is not currently on the WADA Prohibited List. The mechanism (tight junction regulation) does not directly support sport performance.

Research-chemical availability. Larazotide acetate is available from some peptide synthesis vendors for research use. Adult use of an oral peptide for celiac disease (in the context of available gluten-free diet) is not supported by evidence-based recommendations.

Dosing protocols and literature-reported ranges are documented in the approved label or trial publications referenced above.

The larazotide acetate safety profile is favorable based on the cumulative clinical evidence.

Generally well tolerated. Phase 2 and Phase 3 trials reported safety profiles broadly comparable to placebo.

Gastrointestinal effects. Mild GI effects (similar to or only slightly above placebo rates) including diarrhea, flatulence, and abdominal pain.

Headache. Reported at moderate rates, comparable to placebo.

Local action minimizes systemic effects. Because larazotide acetate has minimal systemic absorption (acts locally in intestine), systemic side effects have been limited.

Long-term safety. The Phase 2 and Phase 3 trials documented safety over 12 to 24 weeks of treatment. Longer-term cumulative safety beyond 24 weeks is not well characterized.

No major safety signals have emerged from the clinical development program. The safety profile is one of the favorable aspects of larazotide acetate despite the efficacy challenges that led to Phase 3 discontinuation.

The celiac disease investigational pharmacotherapy class has multiple mechanism approaches.

Larazotide acetate vs Latiglutenase. Latiglutenase is a combination of two gluten-degrading enzymes (ALV003) designed to break down gluten in the stomach before it can trigger immune activation. Different mechanism class (enzymatic degradation vs barrier protection). Latiglutenase has had its own Phase 2 challenges and has not progressed to FDA approval.

Larazotide acetate vs Nexvax2. Nexvax2 was an immune tolerance vaccine that aimed to induce tolerance to gluten antigens. Different mechanism (immune modulation vs barrier protection). The Phase 2 trial was discontinued in 2019 due to lack of efficacy.

Larazotide acetate vs TIMP-GLIA (TAK-101). Nanoparticle-encapsulated gliadin antigen designed to induce immune tolerance. Earlier-stage development.

Larazotide acetate vs KumaMax (Kuma030). Engineered enzyme to degrade gluten in the small intestine. Different mechanism class. Earlier-stage development.

Larazotide acetate vs Vedolizumab / Tofacitinib. Approved IBD/autoimmune drugs being explored off-label or in early trials for refractory celiac. Different mechanism class. Limited efficacy evidence in celiac disease specifically.

The barrier-protection mechanism of larazotide acetate is conceptually elegant but has not yet produced a clinical-stage success. Whether other tight junction modulators or zonulin pathway interventions will emerge from current research pipelines remains uncertain.